-
公开(公告)号：US20240352406A1
公开(公告)日：2024-10-24
申请号：US18639518
申请日：2024-04-18
发明人： Richard C. Jin
CPC分类号： C12N5/0018 , A61K9/06 , A61K9/1658 , A61K47/36 , C12N5/0625 , C12N5/0654 , C12N2501/105 , C12N2501/11 , C12N2501/115 , C12N2501/117 , C12N2501/12 , C12N2501/13 , C12N2501/135 , C12N2501/148 , C12N2501/15 , C12N2501/155 , C12N2501/165 , C12N2501/19 , C12N2501/22 , C12N2501/2301 , C12N2501/2306 , C12N2501/2308 , C12N2501/25 , C12N2502/1142 , C12N2502/1323
摘要： The present invention is drawn, in part, to biocompatible compositions comprising a biocompatible polymer matrix and conditioned cell medium comprising i) a cell culture medium and ii) one or more agents synthesized by and secreted from one or more cells cultured in the cell culture medium, as well as therapeutic uses thereof, particularly in modulating bone and/or gum tissue growth.
-
公开(公告)号：US11999971B2
公开(公告)日：2024-06-04
申请号：US18055312
申请日：2022-11-14
发明人： Felicia J. Pagliuca , George Harb , Lillian Ye
CPC分类号： C12N5/0678 , A61K35/39 , A61P5/50 , A61K2035/126 , C12N2500/46 , C12N2501/11 , C12N2501/117 , C12N2501/119 , C12N2501/15 , C12N2501/155 , C12N2501/16 , C12N2501/19 , C12N2501/415 , C12N2501/999
摘要： Provided herein are methods of producing β cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells.
-
公开(公告)号：US11987806B2
公开(公告)日：2024-05-21
申请号：US17727323
申请日：2022-04-22
发明人： Richard C. Jin
CPC分类号： C12N5/0018 , A61K9/06 , A61K9/1658 , A61K47/36 , C12N5/0625 , C12N5/0654 , C12N2501/105 , C12N2501/11 , C12N2501/115 , C12N2501/117 , C12N2501/12 , C12N2501/13 , C12N2501/135 , C12N2501/148 , C12N2501/15 , C12N2501/155 , C12N2501/165 , C12N2501/19 , C12N2501/22 , C12N2501/2301 , C12N2501/2306 , C12N2501/2308 , C12N2501/25 , C12N2502/1142 , C12N2502/1323
摘要： The present invention is drawn, in part, to biocompatible compositions comprising a biocompatible polymer matrix and conditioned cell medium comprising i) a cell culture medium and ii) one or more agents synthesized by and secreted from one or more cells cultured in the cell culture medium, as well as therapeutic uses thereof, particularly in modulating bone and/or gum tissue growth.
-
公开(公告)号：US20240052319A1
公开(公告)日：2024-02-15
申请号：US18354210
申请日：2023-07-18
发明人： Adrian COOPER , Andre DHARMAWAN , Elena FEDERZONI , Megan LEE , Katie WERLE , Kurt WONG
CPC分类号： C12N5/0688 , C12N5/0018 , C12N2533/52 , C12N2513/00 , C12N2501/115 , C12N2501/119 , C12N2501/39 , C12N2501/01 , C12N2501/999 , C12N2501/117
摘要： The present disclosure relates to methods of differentiating pluripotent stem cells or lung progenitor cells into epithelial or basal cells. The present disclosure also relates to epithelial or basal cells made by such methods, organoids containing such epithelial or basal cells, and methods of using the same. The present disclosure also relates to differentiation media for use in the same.
-
5.发明授权公开(公告)号：US11795437B2
公开(公告)日：2023-10-24
申请号：US17497409
申请日：2021-10-08
发明人： Guan-Yu Chen , Jia-Wei Yang
IPC分类号： C12N5/071
CPC分类号： C12N5/0688 , C12N2501/117 , C12N2501/119 , C12N2501/15 , C12N2501/42 , C12N2501/727 , C12N2513/00 , C12N2533/52 , C12N2533/54
摘要： Disclosed herein is a method for cultivating primary human pulmonary alveolar epithelial cells (HPAEpiC), which includes cultivating the primary HPAEpiC in a first medium containing a basal medium, a culture supplement, and a Rho kinase inhibitor, and a second medium containing the basal medium and the culture supplement in sequence. The culture supplement includes Jagged-1 (JAG-1) peptide, human Noggin protein, transforming growth factor-β (TGF-β) type I receptor inhibitor SB431542, human fibroblast growth factor 7 (hFGF-7), hFGF-10, and glycogen synthase kinase 3 (GSK-3) inhibitor CHIR99021. Also disclosed is a method for preparing a three-dimensional cell culture of alveolar epithelium using the first medium and the second medium.
-
6.发明申请公开(公告)号：US20180282699A1
公开(公告)日：2018-10-04
申请号：US15841004
申请日：2017-12-13
发明人： Sha Jin , Kaiming Ye , Huanjing Bi
IPC分类号： C12N5/071 , C12N5/074 , C12N5/0789 , A61L27/14 , A61L27/36
CPC分类号： C12N5/0677 , A61L27/14 , A61L27/3633 , A61L27/3695 , A61L2430/34 , C12N5/0647 , C12N5/0696 , C12N2501/117 , C12N2501/16 , C12N2501/599 , C12N2533/54 , C12N2533/90
摘要： Human pluripotent stem cells (hPSCs) are promising cell source to produce therapeutic endocrine cells for diabetes treatment. A gel solution made by decellularized tissue-specific extracellular matrix (dpECM) significantly promotes three-dimensional (3D) islet-like organogenesis during induced hPSC differentiation into endocrine lineages. Islet organoids are self-organized even in a two-dimensional (2D) culture mode. Cells derived from hPSCs differentiated on such ECM coated substrates exhibit similar cellular composition to native pancreatic islets. These cells express islet signature markers insulin, PDX-1, C-peptide, MafA, glucagon, somatostatin, and pancreatic polypeptide, and secrete more insulin in response to glucose level compared to a traditional matrix substrate (Matrigel). The dpECM facilitates generating more C-peptide+/glucagon− cells rather than C-peptide+/glucagon+ cells. Remarkably, dpECM also facilitated intra-organoid vascularity by generating endothelial cells and pericytes. Furthermore, dpECM niches also induced intra-organoid microvascularization during pancreatic differentiation.
-
公开(公告)号：US20180258401A1
公开(公告)日：2018-09-13
申请号：US15978918
申请日：2018-05-14
发明人： Francis Karanu , Alireza Rezania
CPC分类号： C12N5/0676 , A61K35/39 , C12N2500/90 , C12N2501/115 , C12N2501/117 , C12N2501/155 , C12N2501/16 , C12N2501/385 , C12N2501/415 , C12N2506/02
摘要： The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention provides methods of characterization of cells differentiated into cells expressing markers characteristic of the pancreatic endocrine lineage utilizing unique surface markers. The present invention also provides methods to enrich or sort cells expressing markers characteristic of the pancreatic endocrine lineage. The present invention also provides methods to deplete cells that may contaminate populations of cells expressing markers characteristic of the pancreatic endocrine lineage formed by the methods of the present invention, thereby reducing the incidence of tumor formation in vivo following transplantation.
-
公开(公告)号：US20180216077A1
公开(公告)日：2018-08-02
申请号：US15905373
申请日：2018-02-26
申请人： YALE UNIVERSITY
发明人： Laura E. NIKLASON , Mahboobe GHAEDI
CPC分类号： C12N5/0688 , A61K35/42 , C12N2501/11 , C12N2501/115 , C12N2501/117 , C12N2501/119 , C12N2501/16 , C12N2501/415 , C12N2506/45 , C12N2533/50 , C12N2533/52 , C12N2533/54 , C12N2533/70 , C12N2533/90
摘要： The present invention relates to compositions and methods for generating populations of tissue precursor cells from pluripotent cells, and preferably induction of stem cells into definitive endoderm to generate anterior foregut endoderm from pluripotent cells. The anterior foregut endoderm cells can then be differentiated into an alveolar epithelial type II cell.
-
9.发明授权公开(公告)号：US09968639B2
公开(公告)日：2018-05-15
申请号：US13925248
申请日：2013-06-24
申请人： Seraxis, Inc.
发明人： William L. Rust
CPC分类号： A61K35/39 , C12N5/0676 , C12N5/0678 , C12N2500/05 , C12N2500/25 , C12N2500/30 , C12N2500/38 , C12N2500/42 , C12N2501/115 , C12N2501/117 , C12N2501/15 , C12N2501/385 , C12N2501/41 , C12N2501/60 , C12N2506/22 , C12N2506/45
摘要： Fresh human pancreas tissue can be used as a source of cells when to identify and select a non-stem cell population that is predisposed to be a source for surrogate pancreatic cells that can be used in treating insulin-dependent diabetes. The progenitors of these surrogate pancreatic cells have no reprogramming genes integrated into their genomes, differentiate to the pancreatic lineage pursuant to a protocol that employs only defined reagents, and are substantially unable to differentiate to the mesodermal lineage.
-
10.发明申请公开(公告)号：US20180087033A1
公开(公告)日：2018-03-29
申请号：US15705896
申请日：2017-09-15
发明人： Xiaofang Xu , Jon Odorico , Erik Forsberg , Amber A. Mael
CPC分类号： C12N5/0676 , A61K9/1652 , A61K9/5036 , A61K35/39 , A61K35/545 , A61K45/06 , C12N2500/05 , C12N2500/22 , C12N2500/25 , C12N2500/38 , C12N2500/44 , C12N2500/90 , C12N2501/01 , C12N2501/105 , C12N2501/11 , C12N2501/115 , C12N2501/117 , C12N2501/155 , C12N2501/16 , C12N2501/33 , C12N2501/335 , C12N2501/385 , C12N2501/395 , C12N2501/40 , C12N2501/727 , C12N2501/91 , C12N2501/998 , C12N2501/999 , C12N2506/02 , C12N2506/45 , G01N33/507
摘要： Methods, kits, compositions, and systems are provided for culturing pluripotent stem cells to produce populations of cells comprising beta-like cells (e.g., pancreatic lineage, glucose-responsive, and/or insulin-producing). In particular, culture conditions are provided that result in the generation of beta-like cells from a starting culture of human pluripotent stem cells.
-
-
-
-
-
-
-
-
-
搜索结果
301 条记录 (耗时 0.037 秒)
